Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis

Lancet

Volumn 355, Issue 9219, 2000, Pages 1936-1942

  Eikelboom, John W ^a   Anand, Sonia S ^a   Malmberg, Klas ^b   Weitz, Jeffrey I ^a   Ginsberg, Jeffrey S ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE HEART FAILURE; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; ST SEGMENT ELEVATION;

EID: 0034600424     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02324-2     Document Type: Article

References (43)

1. Yusuf S., Flather M., Pogue J.et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet. 352:1998;507-514.
2. Fuster V., Badimon L., Badimon J.J., Chesebro J. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:1992;242-250.
3. Furie B., Furie B.C. Molecular and cellular biology of blood coagulation. N Engl J Med. 326:1992;800-806.
4. Theroux P., Fuster V. Acute coronary syndromes. unstable angina and non-Q-wave myocardial infarction Circulation. 97:1998;1195-1206.
5. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 308:1994;81-106.
6. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
7. Weitz J.I., Hirsh J. New antithrombotic agents. Chest. 114:1998;715S-727S.
8. Weitz J.I. Low-molecular-weight heparins. N Engl J Med. 337:1997;688-698.
9. Hirsh J., Warkentin T.E., Raschke R., Granger C., Ohman E.M., Dalen J.E. Heparin and low-molecular-weight heparin. mechanism of action, dosing, considerations, monitoring, efficacy, and safety Chest. 114:1998;489S-510S.
10. Barrowcliffe T.W., Merton R.E., Havercroft S.J., Thunberg L., Lindahl U., Thomas D.P. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides. Thromb Res. 34:1984;125-133.
11. Ofosu F.A., Hirsh J., Esmon C.T.et al. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J. 257:1989;143-150.
12. Beguin S., Mardiguian J., Lindhout T., Hemker H.C. The mode of action of low molecular weight heparin preparation (PK 10169) and two of its major components of thrombin generation in plasma. Thromb Haemost. 61:1989;30-34.
13. Warkentin T.E., Levine M.N., Hirsh J.et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 332:1995;1330-1335.
14. Fareed J., Jeske W., Hoppensteadt D., Clarizio R., Walenga J.M. Low-molecular-weight-heparins. pharmacological profile and product differentiation Am J Cardiol. 82:1998;3L-10L.
15. Yusuf S., Peto R., Lewis J., Collins R., Sleight P. Beta blockade during and after MI. an overview of the randomized trials Prog Cardiovasc Dis. 27:1985;335-371.
16. Theroux P., Ouimet H., McCans J.et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 319:1988;1105-1111.
17. Cohen M., Adams P.C., Hawkins L., Bach M., Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol. 66:1990;1287-1292.
18. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 336:1990;827-830.
19. Cohen M., Adams P.C., Parry G.et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation. 89:1994;81-88.
20. Holdright D., Patel D., Cunningham D.et al. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol. 24:1994;39-45.
21. Gurfinkel E.P., Manos E.J., Mejail R.I.et al. LMWH and versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol. 26:1995;313-318.
22. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet. 354:1999;701-707.
23. Klein W., Buchwald A., Hillis S.E.et al. Fragmin in unstable coronary artery disease study. comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease Circulation. 96:1997;61-68.
24. Cohen M., Demers C., Gurfinkel E.P.et al. A comparison of low-molecular-weight heparin with UFH for unstable coronary artery disease: Efficacy and Safety of Subcutaneous enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 337:1997;447-452.
25. Antman E.M., McCabe C.H., Gurfinkel E.P.et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. results of the thrombolysis in myocardial infarction (TIMI) 11B trial Circulation. 100:1999;1593-1601.
26. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J. 20:1999;1553-1562.
27. Serneri G.G.N., Modesti P.A., Gensini G.F.et al. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Lancet. 345:1995;1201-1204.
28. Theroux P., Waters D., Qiu S.et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation. 88:1993;1045-1048.
29. Moise A., Roos M., Roos M. Aspirin virus heparin in the acute phase of unstable angina. Circulation. 90:1994;1107.
30. Cohen M., Parry G., Adams P.C.et al. Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. Eur Heart J. 15:1994;1196-1203.
31. Correia L.C., Neubauer C., Azevedo A.et al. O papel da heparina de baixo peso molecular na angina instavel, infarto agudo do miocardio e pos-angioplastia percutanea transluminal coronario elevita. Arq Bras Cardiol. 65:1995;475-478.
32. Wallis D.E., Bodin W.E., Califf R.et al. Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with suspected acute myocardial infarction. Am Heart J. 122:1991;949-954.
33. Zwerner P.L., Gore J.M., Corrao J.M.et al. Heparin in the treatment of unstable angina. a randomised prospective trial Circulation. 76:1987;180.
34. Cohen M., Xiong J., Parry G.et al. Prospective comparison of unstable angina versus non-Q-wave myocardial infarction during antithrombotic therapy. J Am Coll Cardiol. 22:1993;1338-1343.
35. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol. 29:1997;1474-1482.
36. Survarna T.T., Parikh J.A., Keshav R.et al. Comparison of clinical outcome of fixed-dose subcutaneous low molecular weight heparin (Tinzaparin) with conventional heparin in unstable angina. a pilot study Indian Heart J. 49:1997;159-162.
37. Bednarkiewicz Z., Krzeminska-Pakula M., Kupesa M.et al. Low molecular weight heparin vs regular heparin in the treatment of patients with unstable angina. J Am Coll Cardiol. 29:1997;409A.
38. Dolovich L.R., Ginsberg J.S., Douketis J.D., Holbrook A.M., Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism. examining some unanswered questions regarding location of treatment, product type, and dosing frequency Arch Intern Med. 160:2000;181-188.
39. Antman E.M., Cohen M., Radley D.et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE Meta-Analysis Circulation. 100:1999;1602-1608.
40. Theroux P., Waters D., Lam J., Juneau M., McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Eng J Med. 327:1992;141-145.
41. Granger C.B., Miller J.M., Bovill E.G.et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with ACS. Circulation. 91:1995;1929-1935.
42. Ernofsson M., Strekerud F., Toss H., Abildgaard U., Wallentin L., Siegbahn A. Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost. 79:1998;491-494.
43. Gold H.K., Torres F.W., Garabedian H.D.et al. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 21:1993;1039-1047.